OPX Biotechnologies and Evonik Industries today announced the two companies have entered into an agreement to jointly develop certain bio-based specialty chemicals. The joint-development agreement signed May 3rd 2013 calls for Opxbio to use its proprietary EDGE (Efficiency Directed Genome Engineering) technology to develop the bio-processes.
Oxea is returning to its old name and its roots.
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
Valerie Diele-Braun resigned from her position as CEO and member of the Executive Board of IMCD at the end of April for personal reasons.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Jens Birgersson becomes new Brenntag CEO
